Penumbra Analyst Ratings
Positive Outlook for Penumbra: Accelerated THUNDER Trial Progress and Thunderbolt System Potential Justify Buy Rating
Penumbra's Growth Trajectory and Market Dominance Reinforce Buy Rating
Piper Sandler Cuts Inari to Neutral; Cites Slowing Growth, DOJ Probe
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX)
Piper Sandler Adjusts Price Target on Penumbra to $290 From $310, Maintains Overweight Rating
Buy Rating Justified by Penumbra's Market Presence and Projected Growth
Penumbra Analyst Ratings
Deutsche Bank Raises Penumbra Price Target to $288 From $257, Maintains Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Penumbra (PEN), BioMarin Pharmaceutical (BMRN) and Insulet (PODD)
Maintaining Buy Rating on Penumbra: Strong Growth Prospects and Strategic Focus
Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN)
Penumbra Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Penumbra (PEN) and BioMarin Pharmaceutical (BMRN)
Hold Rating on Penumbra: Balancing Operational Strengths and Market Expectations
Buy Rating Affirmed: Penumbra's Strong Product Pipeline and Technological Advancements Set to Drive Growth
Truist Financial Remains a Buy on Penumbra (PEN)
RBC Capital Maintains Outperform on Penumbra, Raises Price Target to $289
Penumbra Analyst Ratings
Buy Rating Affirmed for Penumbra Amid Strong Growth Projections and Market Expansion Strategy
No Data